India is attracting foreign debt capital by removing taxes and easing borrowing rules. This move is expected to inject significant liquidity by September 30. Experts believe this will lower short-term interest rates. Target maturity funds are recommended for investors to benefit from these changes. These funds offer predictable returns by holding bonds until maturity.
Retail chains from smaller Indian towns are planning to raise over Rs 7,000 crore through IPOs. These companies see capital markets as a fast route to fund expansion into growing markets beyond metros. This trend reflects a structural shift in consumption patterns, with emerging Bharat becoming a durable engine of growth for organised retail.
Indian banks are significantly increasing rates on foreign-currency deposits to attract overseas residents, testing the central bank's new measures to boost capital inflows and support the rupee. This strategy aims to strengthen the currency amidst high oil prices and intense domestic deposit competition.
Elon Musk's SpaceX is preparing for a historic $75 billion IPO, aiming for a $1.75 trillion valuation despite reporting significant losses. While investor demand is high, concerns linger regarding overvaluation, Elon Musk's continued control, substantial debt, and increasing competition in the commercial space sector.
Helios Mutual Fund is shifting investments from large companies to mid and small companies. This move follows earnings growth trends where mid and small companies are showing much higher growth than large companies. The fund has added Adani Enterprises, Dixon Technologies, and CAMS to its portfolio. It is avoiding sectors like metals and US-facing pharma.
The Indian rupee is projected to average around 96 against the US dollar in FY27. However, this outlook faces potential challenges including dollar strength and crude oil price fluctuations. Despite a widening trade deficit, strong capital inflows and RBI intervention are expected to prevent a sharp depreciation.
Concord Biotech's shares surged over 6% after receiving USFDA approval for its Tofacitinib Tablets in 5 mg and 10 mg strengths. This approval for rheumatoid arthritis and other conditions is expected to bolster its U.S. market presence and product portfolio, targeting a $500 million market opportunity.
Bitcoin is trading near $61,000, down significantly from its peak. Geopolitical tensions and upcoming US economic data are causing caution. Investors are prioritizing capital preservation amid uncertainty. Spot Bitcoin ETFs have seen outflows, impacting market participation. Analysts watch for inflation data to gauge Bitcoin's next move.
MF Performance
Major Indices
